Supply from drugmakers for the stimulant medications most commonly prescribed for ADHD are still falling short of demand, the Food and Drug Administration says, and many Americans who rely on these ...
In September 1984, the Drug Price Competition & Patent Term Restoration Act, commonly known as the Hatch-Waxman Act for its congressional sponsors’ names, was signed into U.S. law. By creating a new ...
A new court ruling has the future use of skinny labels in question, but skinny-label generics have saved Medicare a lot of money over 5 years. Skinny labels, which carve out patent-protected ...
Last week, the Federal Circuit decided Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 23-1169 (Fed. Cir. June 25, 2024), a case that spotlighted the issues of skinny labeling and induced ...
Consumers and lawmakers pushing for cheaper alternatives to the EpiPen, an antidote for life-threatening allergic reactions, and other high-priced drugs are seeking answers about a stubborn backlog of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback